[go: up one dir, main page]

ECSP11011132A - Compuesto amino pirazol - Google Patents

Compuesto amino pirazol

Info

Publication number
ECSP11011132A
ECSP11011132A EC2011011132A ECSP11011132A ECSP11011132A EC SP11011132 A ECSP11011132 A EC SP11011132A EC 2011011132 A EC2011011132 A EC 2011011132A EC SP11011132 A ECSP11011132 A EC SP11011132A EC SP11011132 A ECSP11011132 A EC SP11011132A
Authority
EC
Ecuador
Prior art keywords
pirazol
amino
compound
glioblastoma
leukemia
Prior art date
Application number
EC2011011132A
Other languages
English (en)
Inventor
Timothy Paul Burkholder
Joshua Ryan Clayton
Liandong Ma
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41630090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP11011132(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP11011132A publication Critical patent/ECSP11011132A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención provee compuestos amino pirazol útiles en el tratamiento de trastornos mieloproliferantes crónicos y varios cánceres, por ejemplo, glioblastoma, cáncer de mama, mieloma múltiple, cáncer de próstata, y leucemias.
EC2011011132A 2008-12-16 2011-06-15 Compuesto amino pirazol ECSP11011132A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12285408P 2008-12-16 2008-12-16

Publications (1)

Publication Number Publication Date
ECSP11011132A true ECSP11011132A (es) 2011-07-29

Family

ID=41630090

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011132A ECSP11011132A (es) 2008-12-16 2011-06-15 Compuesto amino pirazol

Country Status (38)

Country Link
US (2) US20100286139A1 (es)
EP (1) EP2379557B1 (es)
JP (1) JP5509217B2 (es)
KR (1) KR101300458B1 (es)
CN (1) CN102232075B (es)
AR (1) AR074240A1 (es)
AU (1) AU2009330503B2 (es)
BR (1) BRPI0923048A2 (es)
CA (1) CA2744714C (es)
CL (1) CL2011001445A1 (es)
CO (1) CO6331442A2 (es)
CR (1) CR20110341A (es)
CY (1) CY1113637T1 (es)
DK (1) DK2379557T3 (es)
DO (1) DOP2011000190A (es)
EA (1) EA019554B1 (es)
EC (1) ECSP11011132A (es)
ES (1) ES2396617T3 (es)
HN (1) HN2011001697A (es)
HR (1) HRP20120918T1 (es)
IL (1) IL213065A0 (es)
JO (1) JO2833B1 (es)
MA (1) MA32900B1 (es)
MX (1) MX2011006441A (es)
MY (1) MY158691A (es)
NZ (1) NZ592641A (es)
PA (1) PA8851101A1 (es)
PE (1) PE20110549A1 (es)
PL (1) PL2379557T3 (es)
PT (1) PT2379557E (es)
SG (1) SG172202A1 (es)
SI (1) SI2379557T1 (es)
SV (1) SV2011003949A (es)
TN (1) TN2011000292A1 (es)
TW (1) TWI440640B (es)
UA (1) UA104743C2 (es)
WO (1) WO2010074947A1 (es)
ZA (1) ZA201103942B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8105633B2 (en) * 2006-03-01 2012-01-31 Spintec Engineering Gmbh Method and apparatus for extraction of arthropod gland
GB2435646A (en) * 2006-03-01 2007-09-05 Spin Tec Engineering Gmbh Apparatus and method of extraction of an arthropod gland
US20110121485A1 (en) * 2006-10-30 2011-05-26 Spintec Engineering Gmbh Method and apparatus for the manufacture of a fiber
KR20130131461A (ko) * 2011-03-07 2013-12-03 폰다지오네 텔레톤 Tfeb 변종 및 그의 용도
MX340816B (es) * 2011-06-15 2016-07-26 Rheinische Friedrich-Wilhelms-Universität Bonn Compuestos que inhiben el glioblastoma y su uso.
CN112755193A (zh) 2012-06-26 2021-05-07 德玛医药 使用卫康醇或其衍生物治疗抗酪氨酸激酶抑制剂的恶性肿瘤的方法
PL400213A1 (pl) 2012-08-01 2014-02-03 Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia Pochodne imidazo[1,2-b]pirydazyno-6-aminy jako inhibitory kinazy JAK-2
RS62713B1 (sr) 2014-08-11 2022-01-31 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
SI3179992T1 (sl) 2014-08-11 2022-09-30 Acerta Pharma B.V. Terapevtske kombinacije zaviralca BTK, zaviralca PD-1 in/ali zaviralca PD-L1
WO2016024232A1 (en) 2014-08-11 2016-02-18 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor and/or a cdk 4/6 inhibitor
ES2849974T3 (es) * 2016-11-17 2021-08-24 Bristol Myers Squibb Co Moduladores de imidazopiridazina de IL-12, IL-23 y/o IFNalfa
WO2018167283A1 (en) 2017-03-17 2018-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma associated neural remodeling
WO2018189335A1 (en) 2017-04-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110305140B (zh) 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059111A2 (en) 2000-12-21 2002-08-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2003137785A (ja) * 2001-08-23 2003-05-14 Takeda Chem Ind Ltd Ｊｎｋ活性化阻害剤
AU2002357379A1 (en) 2001-12-21 2003-07-15 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
RU2405780C2 (ru) 2005-02-16 2010-12-10 Астразенека Аб Химические соединения
BRPI0608160A2 (pt) 2005-02-16 2010-11-09 Astrazeneca Ab anticorpo isolado, célula hospedeira, método de inibir o crescimento de células psma+, e, uso de um anticorpo anti-psma defucosilado
AU2006265840B2 (en) * 2005-07-01 2010-02-11 Irm Llc Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
AR055206A1 (es) * 2005-10-06 2007-08-08 Schering Corp Pirazolo[1, 5 - a]pirimidinas como inhibidoras de proteina quinasa, composiciones farmaceuticas y combinaciones con agentes citostaticos que las comprenden y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
KR20080063806A (ko) * 2005-10-06 2008-07-07 쉐링 코포레이션 단백질 키나제 억제제로서의 피라졸로피리미딘
CA2630884A1 (en) * 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
US7989459B2 (en) * 2006-02-17 2011-08-02 Pharmacopeia, Llc Purinones and 1H-imidazopyridinones as PKC-theta inhibitors
CN101594909A (zh) 2006-09-07 2009-12-02 比奥根艾迪克Ma公司 用于治疗炎性病症、细胞增殖性失调、免疫失调的irak调节剂
BRPI0718266A2 (pt) * 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
EP2155742A1 (en) * 2007-04-18 2010-02-24 AstraZeneca AB 5-aminopyrazol-3-yl-3h-imidazo [4,5-b]pyridine derivatives and their use for the treatment of cancer
EP2152708A1 (en) 2007-05-23 2010-02-17 Pharmacopeia, LLC Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
WO2009062059A2 (en) 2007-11-08 2009-05-14 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors

Also Published As

Publication number Publication date
JP2012512158A (ja) 2012-05-31
US20100152181A1 (en) 2010-06-17
TW201024301A (en) 2010-07-01
CN102232075B (zh) 2013-12-11
UA104743C2 (ru) 2014-03-11
PE20110549A1 (es) 2011-08-04
WO2010074947A1 (en) 2010-07-01
CN102232075A (zh) 2011-11-02
EA201170831A1 (ru) 2011-12-30
NZ592641A (en) 2013-01-25
CR20110341A (es) 2011-07-13
PT2379557E (pt) 2013-01-14
HK1160109A1 (en) 2012-08-10
AU2009330503B2 (en) 2012-06-07
PA8851101A1 (es) 2010-07-27
CA2744714A1 (en) 2010-07-01
MY158691A (en) 2016-10-31
EA019554B1 (ru) 2014-04-30
EP2379557A1 (en) 2011-10-26
CL2011001445A1 (es) 2011-11-11
CY1113637T1 (el) 2016-06-22
CO6331442A2 (es) 2011-10-20
TWI440640B (zh) 2014-06-11
SI2379557T1 (sl) 2013-02-28
JO2833B1 (en) 2014-09-15
DOP2011000190A (es) 2011-07-31
ZA201103942B (en) 2012-08-29
US20100286139A1 (en) 2010-11-11
HRP20120918T1 (hr) 2012-12-31
JP5509217B2 (ja) 2014-06-04
PL2379557T3 (pl) 2013-03-29
IL213065A0 (en) 2011-07-31
SG172202A1 (en) 2011-07-28
BRPI0923048A2 (pt) 2018-09-25
KR20110084993A (ko) 2011-07-26
AR074240A1 (es) 2011-01-05
EP2379557B1 (en) 2012-10-31
HN2011001697A (es) 2013-11-26
ES2396617T3 (es) 2013-02-22
US7897600B2 (en) 2011-03-01
MX2011006441A (es) 2011-07-19
AU2009330503A1 (en) 2010-07-01
KR101300458B1 (ko) 2013-08-30
TN2011000292A1 (en) 2012-12-17
CA2744714C (en) 2013-06-25
DK2379557T3 (da) 2012-12-17
MA32900B1 (fr) 2011-12-01
SV2011003949A (es) 2011-07-21

Similar Documents

Publication Publication Date Title
CO6331442A2 (es) Compuesto amino pirazol
NZ718826A (en) Pyrrolobenzodiazepines and conjugates thereof
JO2788B1 (en) Amido phenoxyendazole compounds beneficial as C-MET inhibitors
EA201171367A1 (ru) Винилиндазолильные соединения
PH12016502066A1 (en) Methods of treating bladder cancer
MX373121B (es) Composiciones y metodos para el tratamiento de leucemia.
MX346924B (es) Compuestos de diarilhidantoina.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2010009669A (es) Terapia de combinacion con antagonistas de c-met y egfr.
CL2012003503A1 (es) Compuestos derivados de morfolin pirimidinas sustituidos, inhibidores de la proteina quinasa atr; composicion farmaceutica, utiles para la prevencion o el tratamiento de tumores cancerigenos.
EA201400178A1 (ru) Лечение рака молочной железы
EA200901074A1 (ru) Лечение метастатической стадии рака предстательной железы дегареликсом
PH12019501393B1 (en) Afucosylated anti-fgfr2iiib antibodies
MX375325B (es) Combinacion de anticuerpo anti-cd20 e inhibidor selectivo de pi3 cinasa.
EA201270606A1 (ru) Новое противоопухолевое применение кабазитаксела
CY1117722T1 (el) Βελτιωμενη αγωγη του πολλαπλου μυελωματος
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
EA201590650A1 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
EA200971067A1 (ru) Триазолиламинопиримидиновые соединения
UA101379C2 (en) Amidophenoxyindazoles useful in the treatment of cancer
EA201992557A1 (ru) Противоопухолевые соединения
TN2011000013A1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
CL2014001265A1 (es) Compuestos derivados de uracilo, inhibidores de la quinasa axl y c-met, utiles en el tratamiento del cancer.
UA100869C2 (ru) Лечение рака яичника с помощью соединения йодонитробензамида в комбинации с противоопухолевыми средствами
CY1114071T1 (el) Ενωσεις βινυλοϊνδαζολυλιου